
Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies according to the variant of concern (VOC). This data suggest that among adult outpatients with mild-to-moderate SARS-CoV-2 infection due to Omicron BA.1 and BA.1.1, early treatment with sotrovimab reduces the time to recovery compared with casirivimab/imdevimab and bamlanivimab/etesevimab. Furthermore, in the same population, early therapy with casirivimab/imdevimab may maintain a role in preventing COVID-19 progression. However, the generalisability of trial results is substantially limited by the early discontinuation of the trial, and firm conclusions cannot be drawn.
Like
Save
Share